(Q37654660)

21 August 2017

1 reference

title

Current progress in targeted therapy for colorectal cancer (English)

1 reference

21 August 2017

1 reference

Jose Ortega

1

1 reference

21 August 2017

Carlos E Vigil

series ordinal

2

1 reference

21 August 2017

Catherine Chodkiewicz

series ordinal

3

1 reference

21 August 2017

publication date

1 January 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

17

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

7-15

1 reference

21 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Angiogenesis: an organizing principle for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Surgical therapy for colorectal metastases to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Trends in long-term survival following liver resection for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

The price tag on progress--chemotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Evaluation of trends in the cost of initial cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

The continuum of care: a paradigm for the management of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700102

10.1177/107327481001700102

21 January 2018

Identifiers

DOI

0 references

1 reference